FR2182914A1 - - Google Patents

Info

Publication number
FR2182914A1
FR2182914A1 FR7311419A FR7311419A FR2182914A1 FR 2182914 A1 FR2182914 A1 FR 2182914A1 FR 7311419 A FR7311419 A FR 7311419A FR 7311419 A FR7311419 A FR 7311419A FR 2182914 A1 FR2182914 A1 FR 2182914A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7311419A
Other languages
French (fr)
Other versions
FR2182914B1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of FR2182914A1 publication Critical patent/FR2182914A1/fr
Application granted granted Critical
Publication of FR2182914B1 publication Critical patent/FR2182914B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7311419A 1972-03-30 1973-03-29 Expired FR2182914B1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (enExample) 1972-03-30 1972-03-30

Publications (2)

Publication Number Publication Date
FR2182914A1 true FR2182914A1 (enExample) 1973-12-14
FR2182914B1 FR2182914B1 (enExample) 1976-05-14

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7311419A Expired FR2182914B1 (enExample) 1972-03-30 1973-03-29

Country Status (12)

Country Link
US (1) US3850941A (enExample)
JP (1) JPS5229318B2 (enExample)
AR (1) AR197709A1 (enExample)
BE (1) BE797554A (enExample)
BR (1) BR7302268D0 (enExample)
CA (1) CA989843A (enExample)
DE (1) DE2315801C3 (enExample)
ES (1) ES413188A1 (enExample)
FR (1) FR2182914B1 (enExample)
GB (1) GB1378375A (enExample)
HU (1) HU167305B (enExample)
SE (1) SE402592B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289192A1 (fr) * 1974-11-01 1976-05-28 Kyorin Seiyaku Kk Pyrazolo(1,5-a)pyridines et medicament contenant ces substances
EP0215438A3 (en) * 1985-09-14 1989-05-24 Kyorin Seiyaku Kabushiki Kaisha Use of 3-isobutyryl-2-isopropylpyrazoloû1,5-a¨pyridine as an anti-rheumatic agent
EP0319902A3 (en) * 1987-12-10 1990-01-31 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (enExample) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
NZ577031A (en) 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
KR20060120208A (ko) 2003-11-21 2006-11-24 콤비네이토릭스, 인코포레이티드 염증성 질환의 치료 방법 및 시약
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP2038279A2 (en) * 2006-06-06 2009-03-25 Avigen, Inc. Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080181876A1 (en) 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
JP2010533173A (ja) * 2007-07-11 2010-10-21 オークランド・ユニサーヴィシズ・リミテッド ピラゾロ［１，５−ａ］ピリジン、及び癌治療におけるその使用
US20090176778A1 (en) * 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009022740A1 (ja) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010005520A2 (en) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
BR112012011237A2 (pt) 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289192A1 (fr) * 1974-11-01 1976-05-28 Kyorin Seiyaku Kk Pyrazolo(1,5-a)pyridines et medicament contenant ces substances
EP0215438A3 (en) * 1985-09-14 1989-05-24 Kyorin Seiyaku Kabushiki Kaisha Use of 3-isobutyryl-2-isopropylpyrazoloû1,5-a¨pyridine as an anti-rheumatic agent
EP0319902A3 (en) * 1987-12-10 1990-01-31 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
US5602165A (en) * 1987-12-10 1997-02-11 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents

Also Published As

Publication number Publication date
SE402592B (sv) 1978-07-10
JPS4897898A (enExample) 1973-12-13
DE2315801C3 (de) 1979-02-22
ES413188A1 (es) 1976-01-16
FR2182914B1 (enExample) 1976-05-14
AR197709A1 (es) 1974-04-30
DE2315801A1 (de) 1973-10-11
HU167305B (enExample) 1975-09-27
AU5376173A (en) 1974-09-26
DE2315801B2 (de) 1978-06-22
BE797554A (fr) 1973-07-16
US3850941A (en) 1974-11-26
GB1378375A (en) 1974-12-27
JPS5229318B2 (enExample) 1977-08-01
BR7302268D0 (pt) 1974-08-29
CA989843A (en) 1976-05-25

Similar Documents

Publication Publication Date Title
JPS4897898A (enExample)
FR2211812A1 (enExample)
CS150471B1 (enExample)
CS152762B1 (enExample)
CS156306B1 (enExample)
CS157377B1 (enExample)
CS157424B1 (enExample)
CS164414B1 (enExample)
CS162228B1 (enExample)
CS159061B1 (enExample)
CS158523B1 (enExample)
CS158490B1 (enExample)
CH564657A5 (enExample)
CH578431A5 (enExample)
BG26628A1 (enExample)
CH268373A4 (enExample)
CH545548A (enExample)
CH559105A5 (enExample)
CH559704A5 (enExample)
CH559790A5 (enExample)
CH559798B5 (enExample)
CH559805B5 (enExample)
CH561355A5 (enExample)
CH563565A5 (enExample)
BG18669A1 (enExample)